|
|
Volumn 61, Issue 11, 2009, Pages 897-898
|
|
Optimizing the future for biotechnology therapies, the key role of protein engineering
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIINFECTIVE AGENT;
ANTINEOPLASTIC AGENT;
CELL PENETRATING PEPTIDE;
CYCLOTIDE;
ENDOPEPTIDASE CLPX;
EPITOPE;
INTEIN;
RECOMBINANT IMMUNOTOXIN BL22;
TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;
UNCLASSIFIED DRUG;
B LYMPHOCYTE;
BINDING AFFINITY;
BIOTECHNOLOGY;
CANCER REGRESSION;
CANCER THERAPY;
CELL MEMBRANE PERMEABILITY;
DRUG DELIVERY SYSTEM;
DRUG PENETRATION;
EDITORIAL;
HAIRY CELL LEUKEMIA;
HUMAN;
IMMUNOGENICITY;
LIGAND BINDING;
MEMBRANE PERMEABILITY;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN DOMAIN;
PROTEIN ENGINEERING;
PROTEIN PROCESSING;
PROTEIN PROTEIN INTERACTION;
PROTEIN TARGETING;
PROTEIN TRANSPORT;
RECEPTOR BINDING;
RECOMBINANT DNA TECHNOLOGY;
REGULATORY T LYMPHOCYTE;
BIOTECHNOLOGY;
PROTEIN ENGINEERING;
|
|
EID: 70349449578
PISSN: 0169409X
EISSN: None
Source Type: Journal
DOI: 10.1016/j.addr.2009.09.001 Document Type: Editorial |
|
Times cited : (2)
|
|
References (0)
|
